Primary Peritoneal Cancer

Also known as: Peritoneal Primary Cancer / Peritoneal Carcinoma / Peritoneal cancer / Malignant peritoneal neoplasm / Malignant neoplasm of peritoneum, unspecified / Malignant peritoneal neoplasm NOS

DrugDrug NameDrug Description
DB11793NiraparibNiraparib is an orally active PARP inhibitor developed by Tesaro to treat ovarian cancer. FDA approval on March 2017.
DB09074OlaparibOlaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular homeostasis, such as DNA transcription, cell cycle regulation, and DNA repair. Olaparib has been shown to inhibit growth of select tumor cell lines in vitro and decrease tumor growth in mouse xenograft models of human cancer both as monotherapy or following platinum-based chemotherapy. Increased cytotoxicity and anti-tumor activity following treatment with olaparib were noted in cell lines and mouse tumor models with deficiencies in BRCA. In vitro studies have shown that olaparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complex, resulting in disruption of cellular homeostasis and cell death. Olaparib is available as oral tablets marketed under the brand name Lynparza and was initially indicated as a maintenance therapy or monotherapy for the treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. On January 12, 2018, FDA expanded the approved use of Lynparza to include chemotherapy-experienced patients with germline breast cancer susceptibility gene (BRCA) mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer. In a randomized clinical trial involving patients with HER2-negative metastatic breast cancer with a germline BRCA mutation, the median progression-free survival for patients taking Lynparza was 7 months compared to 4.2 months for patients taking chemotherapy only. Patient selection for this newly-approved indication can be performed based on an FDA-approved genetic test, called the BRACAnalysis CDx. Moreover, in December of 2018 the FDA further approved the categorization and use of Lynparza (olaparib) as frontline maintenance therapy in ovarian cancer, making the medication the first time a PARP inhibitor has been approved in the first-line maintenance setting [L5086]. This new approval for frontline maintenance now allows patients who have had surgery and complete or partial response to platinum-based therapy after being first diagnosed with the cancer to be treated with olaparib to decrease the risk of recurrence or delay it significantly [L5086]. This approval is based on findings from the phase 3 SOLO-1 trial for olaparib, which demonstrated the capacity for the agent to reduce the risk of disease progression or death by 70% in patients with BRCA-mutant advanced ovarian cancer who were in complete or partial response to platinum-based chemotherapy [L5086]. It is expected that the ability to offer this important first-line maintenance treatment option to eligible patients may slow down or even stop the natural course of disease progression [L5086].
DrugDrug NamePhaseStatusCount
DB00041Aldesleukin1Recruiting1
DB00112Bevacizumab1Active Not Recruiting4
DB00112Bevacizumab1Completed1
DB00188Bortezomib1Completed1
DB00958Carboplatin1Active Not Recruiting2
DB00958Carboplatin1Completed5
DB00958Carboplatin1Recruiting1
DB00493Cefotaxime1Recruiting1
DB00515Cisplatin1Active Not Recruiting1
DB00531Cyclophosphamide1Recruiting2
DB01262Decitabine1Recruiting1
DB01073Fludarabine1Recruiting1
DB09035Nivolumab1Active Not Recruiting2
DB09074Olaparib1Active Not Recruiting1
DB09074Olaparib1Completed1
DB01229Paclitaxel1Active Not Recruiting4
DB01229Paclitaxel1Completed1
DB01229Paclitaxel1Recruiting1
DB12257Platinum1Completed1
DB11730Ribociclib1Recruiting1
DB12376Ricolinostat1Active Not Recruiting1
DB00853Temozolomide1Completed1
DB07232Veliparib1Completed1
DB00112Bevacizumab1 / 2Recruiting1
DB00112Bevacizumab1 / 2Withdrawn1
DB00958Carboplatin1 / 2Completed1
DB00958Carboplatin1 / 2Recruiting2
DB00531Cyclophosphamide1 / 2Withdrawn1
DB00997Doxorubicin1 / 2Terminated1
DB12047Ganetespib1 / 2Terminated1
DB00441Gemcitabine1 / 2Completed1
DB12489Mirvetuximab Soravtansine1 / 2Recruiting1
DB01229Paclitaxel1 / 2Recruiting1
DB01229Paclitaxel1 / 2Terminated1
DB06589Pazopanib1 / 2Terminated1
DB09037Pembrolizumab1 / 2Recruiting1
DB00642Pemetrexed1 / 2Completed1
DB11787Ralimetinib1 / 2Completed1
DB10286Streptococcus pneumoniae type 4 capsular polysaccharide diphtheria crm197 protein conjugate antigen1 / 2Active Not Recruiting1
DB11760Talazoparib1 / 2Recruiting1
DB01217Anastrozole2Completed1
DB00112Bevacizumab2Completed2
DB00112Bevacizumab2Recruiting2
DB00112Bevacizumab2Terminated3
DB00958Carboplatin2Completed1
DB00958Carboplatin2Recruiting2
DB00958Carboplatin2Terminated2
DB00958Carboplatin2Unknown Status1
DB00091Ciclosporin2Completed1
DB00515Cisplatin2Completed1
DB00515Cisplatin2Not Yet Recruiting1
DB00515Cisplatin2Terminated1
DB00531Cyclophosphamide2Completed1
DB00531Cyclophosphamide2Terminated1
DB00997Doxorubicin2Active Not Recruiting1
DB00530Erlotinib2Completed1
DB01073Fludarabine2Completed1
DB00317Gefitinib2Completed1
DB00441Gemcitabine2Completed2
DB00441Gemcitabine2Terminated3
DB00441Gemcitabine2Unknown Status1
DB00619Imatinib2Completed1
DB00724Imiquimod2Active Not Recruiting1
DB05975Iniparib2Completed1
DB04845Ixabepilone2Recruiting1
DB00959Methylprednisolone2Completed1
DB12303Motolimod2Active Not Recruiting1
DB11793Niraparib2Active Not Recruiting2
DB00526Oxaliplatin2Terminated2
DB01229Paclitaxel2Active Not Recruiting1
DB01229Paclitaxel2Completed3
DB01229Paclitaxel2Not Yet Recruiting1
DB01229Paclitaxel2Recruiting1
DB01229Paclitaxel2Terminated1
DB01229Paclitaxel2Unknown Status1
DB01269Panitumumab2Terminated1
DB09037Pembrolizumab2Recruiting1
DB00642Pemetrexed2Completed1
DB08896Regorafenib2Terminated1
DB00020Sargramostim2Active Not Recruiting1
DB00020Sargramostim2Completed1
DB00398Sorafenib2Completed1
DB11941Tasisulam2Completed1
DB01030Topotecan2Completed1
DB12056Trebananib2Active Not Recruiting1
DB07232Veliparib2Terminated1
DB00361Vinorelbine2Completed1
DB01229Paclitaxel2 / 3Completed1
DB11805Saracatinib2 / 3Completed1
DB00316Acetaminophen3Recruiting1
DB06274Alvimopan3Completed1
DB00112Bevacizumab3Recruiting1
DB00958Carboplatin3Recruiting1
DB00958Carboplatin3Unknown Status1
DB01114Chlorphenamine3Recruiting1
DB00477Chlorpromazine3Recruiting1
DB00514Dextromethorphan3Recruiting1
DB00033Interferon gamma-1b3Terminated1
DB09496Octinoxate3Recruiting1
DB01428Oxybenzone3Recruiting1
DB01229Paclitaxel3Completed2
DB01229Paclitaxel3Recruiting1
DB01229Paclitaxel3Unknown Status1
DB00388Phenylephrine3Recruiting1
DB09536Titanium dioxide3Recruiting1
DB12056Trebananib3Completed1
DB00958CarboplatinNot AvailableCompleted1
DB01229PaclitaxelNot AvailableCompleted1
DB12257PlatinumNot AvailableCompleted1